文献速递其他结缔组织病

系统性硬化症血流动力学表型与生存:新肺动脉高压定义的影响

Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.
PubMed 文献 · Ann Rheum Dis · 2019-12-09

该研究在Heidelberg与Zurich前瞻性连续筛查、接受右心导管检查的284例系统性硬化症(SSc)患者中,按第6届PH世界研讨会新肺动脉高压(PAH)定义重新评估血流动力学与临床变量,并随访3.7±3.7年(中位3.4年)行Kaplan-Meier生存分析。结果显示,PVR≥3 WU阈值过高,不利于PAH早期诊断;mPAP 21–24 mm Hg且PVR≥2 WU者已出现早期肺血管病并伴生存下降。

要点

  • mPAP 21–24 mm Hg且PVR≥2 WU的SSc患者已出现6MWD、TAPSE及肺动脉顺应性下降。
  • PVR≥2 WU与长期生存下降相关(p=0.002),多变量分析中PVR与6MWD为独立预后预测因素。
  • 以PVR≥3 WU为阈值仅4例(占整个SSc队列1.4%)可重新分类为显性SSc-APAH。

核心结论

  • 在SSc患者中PVR≥3 WU阈值过高,难以实现PAH早期诊断;PVR≥2 WU已与肺血管病及生存显著下降相关,对轻度PAH的SSc患者可能更合适。

研究设计与样本

  • 研究为前瞻性、连续性筛查队列,纳入Heidelberg或Zurich接受右心导管检查的SSc患者,按新PAH定义重新评估血流动力学与临床变量,排除明显肺或左心疾病者后进行对比分析。
  • 最终数据集包括284例SSc患者,随访3.7±3.7年(中位3.4年),行Kaplan-Meier生存分析。

主要发现

  • 146例(49.2%)mPAP≤20 mm Hg,19.3%为mPAP 21–24 mm Hg,29.4%为mPAP≥25 mm Hg。
  • mPAP轻度升高组中仅4例(占整个SSc队列1.4%)PVR≥3 WU,可重新分类为显性SSc-APAH。
  • 28例(9.8%)mPAP 21–24 mm Hg且PVR≥2 WU者已呈现早期肺血管病,6MWD(p<0.001)、TAPSE(p=0.004)及肺动脉顺应性(p<0.001)下降。
  • PVR≥2 WU与长期生存下降相关(p=0.002)。
  • 多变量分析中PVR与6MWD为独立预后预测因素。

关键数值与推荐

  • 新PAH定义相关阈值:mPAP≤20 mm Hg、21–24 mm Hg、≥25 mm Hg分组;PVR≥3 WU可重新分类为显性SSc-APAH;PVR≥2 WU与早期肺血管病及生存下降相关。

临床怎么用

  • 对SSc筛查人群应关注mPAP 21–24 mm Hg且PVR≥2 WU的早期肺血管病表型,结合6MWD、TAPSE与肺动脉顺应性评估,不宜仅以PVR≥3 WU作为早期诊断门槛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In this study, we investigated the impact of the new haemodynamic definition of pulmonary arterial hypertension (PAH) as proposed by the 6th PH World Symposium on phenotypes and survival in patients with systemic sclerosis (SSc). METHODS: In SSc patients who were prospectively and consecutively screened for PAH including right heart catheterisation in Heidelberg or Zurich, haemodynamic and clinical variables have been reassessed according to the new PAH definition. Patients have been followed for 3.7±3.7 (median 3.4) years; Kaplan-Meier survival analysis was performed. Patients with significant lung or left heart disease were excluded from comparative analyses. RESULTS: The final dataset included 284 SSc patients, 146 patients (49.2%) had mean pulmonary arterial pressure (mPAP) ≤20 mm Hg, 19.3% had mPAP 21-24 mm Hg and 29.4% had mPAP ≥25 mm Hg. In the group of mildly elevated mPAP, only four patients (1.4% of the whole SSc cohort) had pulmonary vascular resistance (PVR) values ≥3 Wood Units (WU) and could be reclassified as manifest SSc-APAH. Twenty-eight (9.8%) patients with mPAP of 21-24 mm Hg and PVR ≥2 WU already presented with early pulmonary vascular disease with decreased 6 min walking distance (6MWD) (p<0.001), TAPSE (p=0.004) and pulmonary arterial compliance (p<0.001). A PVR ≥2 WU was associated with reduced long-term survival (p=0.002). PVR and 6MWD were independent prognostic predictors in multivariate analysis. CONCLUSION: The data of this study show that a PVR threshold ≥3 WU is too high to enable an early diagnosis of PAH. A PVR threshold ≥2 WU was already associated with pulmonary vascular disease, significantly reduced survival and would be more appropriate in SSc patients with mild PAH.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2019. PMID: 31818805. doi:10.1136/annrheumdis-2019-216476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。